Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer
Nina G Steele,Eileen S Carpenter,Samantha B Kemp,Veerin R Sirihorachai,Stephanie The,Lawrence Delrosario,Jenny Lazarus,El-Ad David Amir,Valerie Gunchick,Carlos Espinoza,Samantha Bell,Lindsey Harris,Fatima Lima,Valerie Irizarry-Negron,Daniel Paglia,Justin Macchia,Angel Ka Yan Chu,Heather Schofield,Erik-Jan Wamsteker,Richard Kwon,Allison Schulman,Anoop Prabhu,Ryan Law,Arjun Sondhi,Jessica Yu,Arpan Patel,Katelyn Donahue,Hari Nathan,Clifford Cho,Michelle A Anderson,Vaibhav Sahai,Costas A Lyssiotis,Weiping Zou,Benjamin L Allen,Arvind Rao,Howard C Crawford,Filip Bednar,Timothy L Frankel,Marina Pasca di Magliano
DOI: https://doi.org/10.1038/s43018-020-00121-4
Abstract:Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor microenvironment that renders it largely refractory to immunotherapy. We implemented a multimodal analysis approach to elucidate the immune landscape in PDA. Using a combination of CyTOF, single-cell RNA sequencing, and multiplex immunohistochemistry on patient tumors, matched blood, and non-malignant samples, we uncovered a complex network of immune-suppressive cellular interactions. These experiments revealed heterogeneous expression of immune checkpoint receptors in individual patient's T cells and increased markers of CD8+ T cell dysfunction in advanced disease stage. Tumor-infiltrating CD8+ T cells had an increased proportion of cells expressing an exhausted expression profile that included upregulation of the immune checkpoint TIGIT, a finding that we validated at the protein level. Our findings point to a profound alteration of the immune landscape of tumors, and to patient-specific immune changes that should be taken into account as combination immunotherapy becomes available for pancreatic cancer.